Time is brain: is MRI the clock?
OBJECTIVE
MRI is increasingly used as the primary imaging modality in acute stroke, since it allows treatment based on individual pathophysiology rather than strict time windows.


RESULTS
PET studies have confirmed that regions with disturbed diffusion frequently indicate irreversible tissue damage, although they may in part be viable. The mismatch between a larger perfusion deficit and a smaller diffusion abnormality contains both critically hypoperfused regions as well as oligemic regions. Although mismatch is thus not perfect, recent prospective trials have convincingly shown that mismatch patients treated with revascularization therapies benefit from reperfusion, while patients without mismatch do not. This is particularly important for patients presenting beyond the first three hours. In addition, several studies have investigated MRI as a tool to assess the risk of thrombolytic treatment. Parameters reflecting severe ischemia, blood-brain barrier damage and preexisting small-vessel disease emerge as risk factors for intracerebral hemorrhage, while microbleeds are not clearly associated with an increased risk.


CONCLUSIONS
Based on data from prospective trials, the mismatch concept is an acceptable method to identify patients who benefit from recanalization therapies. The concept, however, still needs to be further improved and standard definitions are required before widespread use can be recommended.
Neumann-Haefelin
Tobias
T
Department of Neurology, Goethe-University Frankfurt, Frankfurt, Germany. tnh@rz.uni-frankfurt.de
Steinmetz
Helmuth
H
D001812:Blood-Brain Barrier / Q000473:pathology / Q000503:physiopathology; D002545:Brain Ischemia; D002543:Cerebral Hemorrhage / Q000209:etiology; D004058:Diffusion; D006801:Humans; D049292:Leukoaraiosis / Q000473:pathology; D008279:Magnetic Resonance Imaging / Q000706:statistics & numerical data; D010477:Perfusion; D049268:Positron-Emission Tomography; D011446:Prospective Studies; D012307:Risk Factors; D020521:Stroke / Q000175:diagnosis / Q000473:pathology; D015912:Thrombolytic Therapy / Q000009:adverse effects; D013997:Time Factors